Le Lézard
Classified in: Health
Subject: PLW

Orexo announces new US patent for ZUBSOLV®


UPPSALA, Sweden, Dec. 30, 2020 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV®, Orexo's sublingual buprenorphine and naloxone tablet (CII) for the treatment of opioid use disorder.

The new patent, US Patent No. 10,874,661, expires in September 2032 and further strengthens the company's intellectual property for ZUBSOLV® in the US. Orexo will now have six patents listed in the Orange Book for ZUBSOLV®.

Nikolaj Sørensen, President and CEO, said: "I am pleased to announce that we have further enhanced our patent protection of ZUBSOLV® with a new patent granted in the US. Strong patent protection is the foundation on which we finance and develop new innovative products to the benefit of patients and society. We continue to obtain strong patent protection of our products,

and the quality of our patents was demonstrated in 2018 by the US Court of Appeals for the Federal Circuit when one of our ZUBSOLV® patents was found valid and infringed by a generic company. With this new patent we stand even stronger and are well positioned to continue to play an important role in helping patients suffering from opioid addiction."

For further information, please contact:

Orexo AB (publ.)

Nikolaj Sørensen, President and CEO


Lena Wange, IR & Communications Director

Tel: +46 (0)18 780 88 00


Tel: +46 (0)18 780 88 00

Email: [email protected]


Email: [email protected]

About Orexo

Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the US market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2019 amounted to SEK 844.8 million and the number of employees was 127. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as an ADR on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.

For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.

The information was submitted for publication at 8 am CET, on December 30, 2020.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/orexo/r/orexo-announces-new-us-patent-for-zubsolv-,c3262514

The following files are available for download:

https://mb.cision.com/Main/694/3262514/1354804.pdf

Orexo announces new US patent for ZUBSOLV®

SOURCE Orexo


These press releases may also interest you

at 08:10
Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, announced today the appointment of a new independent director, Neela Patel, Ph.D., to the company's Board of Directors. Dr. Patel is a seasoned...

at 08:08
As a global leader in its industry, it's vital for a company like USANA to maintain a strong human resources department to ensure employees feel safe and taken care of. USANA would like to congratulate its vice president of HR, Mike Sessions on his...

at 08:08
Aspen Neuroscience, Inc., a California-based private biotechnology company developing personalized regenerative therapies, has received a CLIN2 grant award of $8 million from the California Institute for Regenerative Medicine (CIRM), the world's...

at 08:07
The American Red Cross encourages families to prepare for the fast-approaching summer swim season by learning to be "water smart." Research shows that participation in formal water safety and swim lessons can reduce the risk of drowning by 88% for...

at 08:07
KeyCare, the nation's first Epic-based virtual care company, announced today that it is collaborating with Group Health Cooperative of South Central Wisconsin (GHC-SCW) to provide 24x7 urgent care in all 50 states via virtual visits through GHC-SCW's...

at 08:05
BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced the formation of its Scientific Advisory Board (SAB)....



News published on and distributed by: